|
PPN: |
1746460873 
|
|
Titel: |
|
|
Personen: |
|
|
Ort/Jahr: |
Totowa, NJ : Humana Press, 2011 |
|
Sprache/n: |
Englisch |
|
Copyright-Datum: |
©2012 |
|
Umfang: |
1 online resource (376 pages) |
|
Schriftenreihe: |
|
|
Anmerkung: |
Description based on publisher supplied metadata and other sources. |
|
Bibliogr. Zusammenhang: |
|
|
ISBN: |
978-1-61779-407-0
Weitere Ausgaben: 978-1-62703-876-8 (Printausgabe)
|
|
Schlagwörter: |
|
|
Klassifikation: |
|
 |
Inhalt:
|
This book describes recent ground-breaking developments in melanoma treatment in the arena of targeted therapeutics. The contents explore both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
Intro -- Targeted Therapeutics in Melanoma -- Preface -- Cracking the Melanoma Nut -- Acknowledgments -- Contents -- Contributors -- Part I: Advances in Melanoma Biology -- Chapter 1: Molecular Targets and Subtypes in Melanoma -- Introduction -- BRAF -- NRAS -- PI3K-AKT Pathway -- c-KIT -- GNAQ -- Conclusions -- References -- Chapter 2: Melanoma Genomics -- Gene Expression Profiling of Distinct Phases of Melanoma Progression -- Gene Expression Profiles of Primary Melanoma -- Gene Expression Profiling of Metastatic Melanoma -- Conclusions -- References -- Chapter 3: Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma -- Evidence for Existence of Biologic Subsets of Melanoma -- Kinase Mutations and Clinical Response to Kinase Inhibitors -- B-Raf -- c-kit -- New Pathways Showing Heterogeneity Among Individual Melanoma Patients -- Gene Expression Profiling and Clinical Response to Melanoma Vaccines -- Molecular Features Associated with Response to Chemotherapy -- Biomarkers as a Tool to Determine Mechanisms of Therapeutic Resistance -- Predictive Biomarkers from Non-Tumor Tissue: Serum and Germline DNA -- The Evolving Future of Melanoma Therapy -- References -- Part II: Signaling Molecules as Molecular Targets -- Chapter 4: KIT as a Therapeutic Target for Melanoma -- Introduction -- KIT as a Proto-Oncogene -- The Role of KIT in Cancer -- KIT Tyrosine Kinase Inhibitors -- Overcoming Resistance to Tyrosine Kinase Inhibition -- Is KIT Amplification or Mutation More Important? -- Conclusions -- References -- Chapter 5: Targeted Inhibition of B-Raf -- Introduction -- The MAPK Pathway -- BRAF Mutations in Melanoma -- Preclinical Studies -- RAF Inhibition of BRAF Wild-Type Cells Leads to Activation of the MAPK Pathway -- RAF Inhibition of BRAF-Mutated Melanoma Causes Melanoma Cell Death.
|
|
Links zum Titel:
|
|
|
Produktsigel: |
ZDB-30-PQE |
